Share:  
|

References

(1) Fritsch P.O., Ruiz-Maldonado R. Stevens-Johnson Syndrome - Toxic Epidermal Necrolysis. In: Freedberg I.M., Eisen A.Z., Wolff K., Austen K.F., Goldsmith L.A., Katz S.I., Fitzpatrick T.B., editor. Fitzpatrick's Dermatology in General Medicine. Fifth ed. Toronto: McGraw-Hill; 1999. p. 644--650.

(2) Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Archives of Dermatology 1993 Jan;129(1):92-96.

(3) Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Archives of Dermatology 1990 Jan;126(1):37-42.

(4) Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Archives of Dermatology 1991 Jun;127(6):839-842.

(5) Naldi L, Locati F, Marchesi L, Cainelli T. Incidence of toxic epidermal necrolysis in Italy. Archives of Dermatology 1990 Aug;126(8):1103-1104.

(6) Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Archives of Dermatology 1990 Jan;126(1):43-47.

(7) Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Archives of Dermatology 1987 Sep;123(9):1160-1165.

(8) Mittmann N, Knowles SR, Gomez M, Fish JS, Cartotto R, Shear NH. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug safety : an international journal of medical toxicology and drug experience 2004;27(7):477-487.

(9) Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Archives of Dermatology 1995 May;131(5):539-543.

(10) Neuman MG, Malkiewicz IM, Shear NH. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clinical biochemistry 2000 Oct;33(7):517-524.

(11) Hewitt J, Ormerod AD. Toxic epidermal necrolysis treated with cyclosporin. Clinical and experimental dermatology 1992 Jul;17(4):264-265.

(12) Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. The Journal of trauma 2000 Mar;48(3):473-478.

(13) Trautmann A, Klein CE, Kampgen E, Brocker EB. Severe bullous drug reactions treated successfully with cyclophosphamide. The British journal of dermatology 1998 Dec;139(6):1127-1128.

(14) Redondo P, de Felipe I, de la Pena A, Aramendia JM, Vanaclocha V. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. The British journal of dermatology 1997 Apr;136(4):645-646.

(15) Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Annals of Surgery 1986 Nov;204(5):503-512.

(16) Kelemen JJ,3rd, Cioffi WG, McManus WF, Mason AD,Jr, Pruitt BA,Jr. Burn center care for patients with toxic epidermal necrolysis. Journal of the American College of Surgeons 1995 Mar;180(3):273-278.

(17) Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Archives of Dermatology 2003 Jan;139(1):33-36.

(18) Paquet P, Jacob E, Damas P, Pierard GE. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns : journal of the International Society for Burn Injuries 2001 Sep;27(6):652-655.

(19) Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Archives of Dermatology 2003 Jan;139(1):26-32.

(20) Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 Oct 16;282(5388):490-493.

(21) Phan TG, Wong RC, Crotty K, Adelstein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. The Australasian Journal of Dermatology 1999 Aug;40(3):153-157.

(22) Tan A, Tan HH, Lee CC, Ng SK. Treatment of toxic epidermal necrolysis in AIDS with intravenous immunoglobulins. Clinical and experimental dermatology 2003 May;28(3):269-271.

(23) Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. Journal of the American Academy of Dermatology 2002 Oct;47(4):548-552.

(24) Al-Mutairi N, Arun J, Osama NE, Amr Z, Mazen AS, Ibtesam e, et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. International journal of dermatology 2004 Nov;43(11):847-851.

(25) Trent JT, Kerdel FA. Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis. Archives of Dermatology 2003 Aug;139(8):1081.

(26) Sidwell RU, Swift S, Yan CL, Porter W, Thompson EM, Clark JA, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin. International journal of clinical practice 2003 Sep;57(7):643-645.

(27) Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Dermato-Venereologica 2003;83(6):430-432.

(28) Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology (Basel, Switzerland) 2001;203(1):45-49.

(29) Magina S, Lisboa C, Goncalves E, Conceicao F, Leal V, Mesquita-Guimaraes J. A case of toxic epidermal necrolysis treated with intravenous immunoglobin. The British journal of dermatology 2000 Jan;142(1):191-192.

(30) Mayorga C, Torres MJ, Corzo JL, Sanchez-Sabate E, Alvarez J, Vera A, et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology 2003 Jul;91(1):86-91.

(31) Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? The Journal of burn care & rehabilitation 2004 Jan-Feb;25(1):81-88.

(32) Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. The Journal of burn care & rehabilitation 2004 May-Jun;25(3):246-255.

(33) Cheriyan S, Patterson R, Greenberger PA, Grammer LC, Latall J. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proceedings : The Official Journal of Regional and State Allergy Societies 1995 Jul-Aug;16(4):151-155.

(34) Heng MC. Drug-induced toxic epidermal necrolysis. The British journal of dermatology 1985 Nov;113(5):597-600.

(35) Kakourou T, Klontza D, Soteropoulou F, Kattamis C. Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European journal of pediatrics 1997 Feb;156(2):90-93.

(36) Pasricha JS, Khaitan BK, Shantharaman R, Mital A, Girdhar M. Toxic epidermal necrolysis. International journal of dermatology 1996 Jul;35(7):523-527.

(37) Patterson R, Miller M, Kaplan M, Doan T, Brown J, Detjen P, et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Annals of Allergy 1994 Jul;73(1):27-34.

(38) Parsons JM. Toxic epidermal necrolysis. International journal of dermatology 1992 Nov;31(11):749-768.

(39) Stables GI, Lever RS. Toxic epidermal necrolysis and systemic corticosteroids. The British journal of dermatology 1993 Mar;128(3):357.

(40) Tegelberg-Stassen MJ, van Vloten WA, Baart de la Faille,H. Management of nonstaphylococcal toxic epidermal necrolysis: follow-up study of 16 case histories. Dermatologica 1990;180(3):124-129.

(41) Patterson R, Dykewicz MS, Gonzalzles A, Grammer LC, Green D, Greenberger PA, et al. Erythema multiforme and Stevens-Johnson syndrome. Descriptive and therapeutic controversy. Chest 1990 Aug;98(2):331-336.

(42) Patterson R, Grammer LC, Greenberger PA, Lawrence ID, Zeiss CR, Detjen PF, et al. Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS. Allergy Proceedings : The Official Journal of Regional and State Allergy Societies 1992 Mar-Apr;13(2):89-95.

(43) Tripathi A, Ditto AM, Grammer LC, Greenberger PA, McGrath KG, Zeiss CR, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy and Asthma Proceedings : The Official Journal of Regional and State Allergy Societies 2000 Mar-Apr;21(2):101-105.

(44) Engelhardt SL, Schurr MJ, Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. The Journal of burn care & rehabilitation 1997 Nov-Dec;18(6):520-524.

(45) Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. The Journal of burn care & rehabilitation 2000 May-Jun;21(3):199-204.

(46) Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Archives of Dermatology 1987 Sep;123(9):1160-1165.

(47) Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. Journal of the American Academy of Dermatology 1985 Oct;13(4):623-635.

(48) Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. The New England journal of medicine 1995 Dec 14;333(24):1600-1607.

(49) Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns : journal of the International Society for Burn Injuries 1996 Jun;22(4):275-278.

(50) Heimbach DM, Engrav LH, Marvin JA, Harnar TJ, Grube BJ. Toxic epidermal necrolysis. A step forward in treatment. JAMA : the journal of the American Medical Association 1987 Apr 24;257(16):2171-2175.

(51) Jones WG, Halebian P, Madden M, Finkelstein J, Goodwin CW. Drug-induced toxic epidermal necrolysis in children. Journal of pediatric surgery 1989 Feb;24(2):167-170.

(52) Nethercott JR, Choi BC. Erythema multiforme (Stevens-Johnson syndrome)--chart review of 123 hospitalized patients. Dermatologica 1985;171(6):383-396.

(53) Prendiville JS, Hebert AA, Greenwald MJ, Esterly NB. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. The Journal of pediatrics 1989 Dec;115(6):881-887.

(54) Taylor JA, Grube B, Heimbach DM, Bergman AB. Toxic epidermal necrolysis. A comprehensive approach. Multidisciplinary management in a burn center. Clinical pediatrics 1989 Sep;28(9):404-407.

(55) Haber J, Hopman W, Gomez M, Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. The Journal of burn care & rehabilitation 2005 Jan-Feb;26(1):33-41.

(56) Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999 Jun 26;353(9171):2190-2194.

(57) Hallgren J, Tengvall-Linder M, Persson M, Wahlgren CF. Stevens-Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug. Journal of the American Academy of Dermatology 2003 Nov;49(5 Suppl):S267-9.

(58) Canadian Adverse Drug Reaction Monitoring Program. Health Canada has asked Pfizer to suspend sales of its drug BextraT and informs canadians of new restrictions on the use of Celebrex®. 2005;2005-17.

(59) Perna AG, Woodruff CA, Markus RF, Hsu S. Toxic epidermal necrolysis as a complication of treatment with celecoxib. Dermatology online journal [computer file] 2003 Dec;9(5):25.

(60) Friedman B, Orlet HK, Still JM, Law E. Toxic epidermal necrolysis due to administration of celecoxib (Celebrex). Southern medical journal 2002 Oct;95(10):1213-1214.

(61) Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Archives of Dermatology 1987 Sep;123(9):1171-1173.

(62) Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004 Apr 1;428(6982):486.

(63) Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proceedings of the National Academy of Sciences of the United States of America 2005 Mar 15;102(11):4134-4139.

(64) Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. The Journal of clinical investigation 1988 Dec;82(6):1826-1832.

(65) Schlienger RG, Knowles SR, Shear NH. Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998 Oct;51(4):1172-1175.

(66) Ohtani T, Hiroi A, Sakurane M, Furukawa F. Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine. The British journal of dermatology 2003 May;148(5):1035-1039.

(67) Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clinical pharmacology and therapeutics 1992 May;51(5):522-526.

(68) Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Annals of Internal Medicine 1986 Aug;105(2):179-184.

(69) Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy. Drug safety : an international journal of medical toxicology and drug experience 2001;24(4):239-247.